Elicio Therapeutics Inc.

NASDAQ: ELTX · Real-Time Price · USD
11.80
1.96 (19.92%)
At close: Aug 18, 2025, 1:44 PM

Elicio Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 1.17M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.65M 25.94M 1.46M 540K n/a
Cost of Revenue
281K 278K 583K 290K 293K 290K 286K n/a n/a 48K 241K 290K n/a 228K 656K 217K 206K n/a
Gross Profit
-281K -278K 583K -290K -293K -290K -286K n/a n/a -48K -241K -290K n/a 1.42M 25.29M 1.24M 334K n/a
Operating Income
-10.09M -10.74M -13.48M -10.34M -10.92M -10.24M -9.39M -10.77M -7.78M -7.8M -5.96M -5.77M -6.23M -14.48M 14.63M -15.76M -18.24M -6.19M
Interest Income
168K 210K 305K 185K 137K 150K 75K 246K 39K 10K 54.83K 10K n/a 1.36M 876.25K 110K 124K 1.8K
Pretax Income
-10.56M -11.21M -14M -18.84M -7.23M -11.83M -8.95M -10.66M -7.56M -8.03M -6.65M -7.2M -7.3M -14.24M 14.89M -15.7M -17.07M -6.19M
Net Income
-10.56M -11.21M -14M -18.84M -7.23M -11.83M -8.95M -10.66M -7.56M -8.03M -6.65M -7.2M -7.3M -14.24M 14.89M -15.7M -17.07M -6.19M
Selling & General & Admin
3.08M 2.96M 2.77M 3.14M 2.74M 2.68M 3.23M 3.51M 2.83M 2.32M 1.67M 1.18M 1.19M 4.27M 4.01M 3.74M 4.16M 1.64M
Research & Development
7.01M 7.78M 10.71M 7.21M 8.18M 7.56M 6.16M 7.26M 4.94M 5.48M 4.29M 4.59M 5.04M 11.63M 6.64M 13.26M 14.42M 4.55M
Other Expenses
-281K -278K -305K -290K -293K -290K -286K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
9.81M 10.46M 13.17M 10.05M 10.63M 9.95M 9.11M 10.77M 7.78M 7.8M 5.96M 5.77M 6.23M 15.9M 10.65M 17M 18.58M 6.19M
Interest Expense
194K 176K 234K 137K 49K 36K 2K 1K 714K 342K 90.84K 1.08M 1.07M n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 2.68M 2.92M n/a n/a n/a
Cost & Expenses
10.09M 10.74M 13.48M 10.34M 10.92M 10.24M 9.39M 10.77M 7.78M 7.8M 5.96M 5.77M 6.23M 16.13M 11.31M 17.22M 18.78M 6.19M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 463.52K n/a n/a n/a n/a n/a n/a 1.8K
Shares Outstanding (Basic)
16.06M 12.95M 12.2M 13.58M 11.28M 10.27M 9.6M 4.08M 3.1M 3.2M 3.1M 3.18M 3.09M 3M 3M 2.98M 2.97M 13.31M
Shares Outstanding (Diluted)
16.06M 12.95M 12.2M 13.58M 11.28M 10.27M 9.6M 4.08M 3.1M 3.2M 3.1M 3.18M 3.09M 3M 3M 2.98M 2.97M 13.31M
EPS (Basic)
-0.66 -0.87 -1.15 -1.39 -0.64 -1.15 -0.93 -2.61 -2.44 -2.51 -2.15 -2.27 -2.37 -4.75 4.97 -5.26 -5.75 -0.47
EPS (Diluted)
-0.66 -0.87 -1.15 -1.39 -0.64 -1.15 -0.93 -2.61 -2.44 -2.51 -2.15 -2.27 -2.37 -4.75 4.97 -5.26 -5.75 -0.47
EBITDA
-10.09M -10.76M -13.46M -18.41M -6.89M -11.5M -8.77M -10.38M -6.84M -7.7M -6.2M -5.67M -6.23M -14.01M 15.11M -15.54M -16.87M -6.14M
EBIT
-10.37M -11.03M -13.77M -18.7M -7.18M -11.79M -8.95M -10.66M -6.84M -7.69M -6.56M -6.12M -6.23M -14.24M 14.89M -15.7M -17.07M -6.19M
Depreciation & Amortization
281K 278K 305K 290K 293K 290K 286K 273K 501K 48K 241K 290K 105.21K 228K 223K 217K 206K 52.3K